AstraZeneca (AZN) Says Sales Surged 12% in Q4, Long-Term Growth Trends Set to Continue, Analysts Impressed
Tweet Send to a Friend
AstraZeneca (NYSE: AZN), the Anglo-Swedish pharma titan, said that its fourth-quarter sales soared 12% to just over $7 billion. Revenue ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
